Fusion-positive rhabdomyosarcoma (FP-RMS) is a highly aggressive childhood malignancy which mainly treated by conventional chemotherapy, surgery and radiation therapy. Since radiotherapy associated with high burden of late side effects in pediatric patients, addition radiosensitizers would be beneficial. Here, we thought to assess the role fenretinide, potential agent for FP-RMS treatment, as r...